Stifel Nicolaus Increases SAGE Therapeutics (SAGE) Price Target to $239.00
SAGE Therapeutics (NASDAQ:SAGE) had its price target raised by Stifel Nicolaus from $198.00 to $239.00 in a report issued on Tuesday. The firm currently has a buy rating on the biopharmaceutical company’s stock.
A number of other research analysts also recently commented on SAGE. ValuEngine upgraded SAGE Therapeutics from a buy rating to a strong-buy rating in a report on Wednesday, May 2nd. Cowen reiterated a buy rating on shares of SAGE Therapeutics in a report on Thursday, May 3rd. Canaccord Genuity reiterated a buy rating and issued a $210.00 price objective on shares of SAGE Therapeutics in a report on Thursday, May 3rd. BidaskClub upgraded SAGE Therapeutics from a sell rating to a hold rating in a report on Monday, May 14th. Finally, LADENBURG THALM/SH SH initiated coverage on SAGE Therapeutics in a report on Wednesday, June 6th. They issued a buy rating and a $230.00 price objective on the stock. Two investment analysts have rated the stock with a sell rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. SAGE Therapeutics presently has a consensus rating of Buy and an average target price of $199.19.
SAGE Therapeutics opened at $148.36 on Tuesday, according to Marketbeat.com. SAGE Therapeutics has a one year low of $59.57 and a one year high of $195.97.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. US Bancorp DE boosted its position in shares of SAGE Therapeutics by 5,593.3% in the 2nd quarter. US Bancorp DE now owns 854 shares of the biopharmaceutical company’s stock valued at $133,000 after purchasing an additional 839 shares during the period. Creative Planning acquired a new stake in shares of SAGE Therapeutics in the 2nd quarter valued at about $210,000. Atria Investments LLC acquired a new stake in shares of SAGE Therapeutics in the 2nd quarter valued at about $218,000. Tiverton Asset Management LLC acquired a new stake in shares of SAGE Therapeutics in the 2nd quarter valued at about $229,000. Finally, World Asset Management Inc acquired a new stake in shares of SAGE Therapeutics in the 2nd quarter valued at about $252,000.
SAGE Therapeutics Company Profile
Sage Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system disorders. Its lead product candidate comprises brexanolone, a proprietary intravenous formulation of allopregnanolone that has completed III clinical trials for the treatment of post-partum depression (PPD).
Further Reading: How to Track your Portfolio in Google Finance
Receive News & Ratings for SAGE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAGE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.